Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Panitumumab |
Synonyms | |
Therapy Description |
Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Panitumumab | Vectibix | ABX-EGF | EGFR Antibody 65 | Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS wild-type | colorectal cancer | predicted - sensitive | Panitumumab | FDA approved - On Companion Diagnostic | Actionable | Vectibix (panitumumab) is FDA approved for metastatic colorectal patients that are NRAS wild-type, as detected by a companion diagnostic (FDA.gov). | detail... detail... |
NRAS A146X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 4, codon 146 mutations is contraindicated (FDA.gov). | detail... |
NRAS A59X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov). | detail... |
NRAS G12X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov). | detail... |
NRAS G13X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 13 mutations is contraindicated (FDA.gov). | detail... |
NRAS K117X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 4, codon 117 mutations is contraindicated (FDA.gov). | detail... |
NRAS Q61X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 61 mutations is contraindicated (FDA.gov). | detail... |
BRAF V600E | rectum cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org). | detail... |
BRAF V600E | colorectal cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab), as a monotherapy, is not indicated for use in metastatic colorectal cancer patients with BRAF V600E (PMID: 36307056; ESMO.org). | 36307056 detail... |
BRAF V600E | colon cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org). | detail... |
BRAF wild-type | colon cancer | predicted - sensitive | Panitumumab | Guideline | Actionable | Vectibix (panitumumab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic colon cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
BRAF wild-type | rectum cancer | predicted - sensitive | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is included in guidelines for patients with advanced or metastatic rectal cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
NRAS exon2 | rectum cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org). | detail... |
NRAS exon2 | colorectal cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 2 mutations (PMID: 36307056; ESMO.org). | 36307056 detail... |
NRAS exon2 | colon cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org). | detail... |
NRAS exon3 | colorectal cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 3 mutations (PMID: 36307056; ESMO.org). | 36307056 detail... |
NRAS exon3 | rectum cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org). | detail... |
NRAS exon3 | colon cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org). | detail... |
NRAS exon4 | rectum cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org). | detail... |
NRAS exon4 | colorectal cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in metastatic colorectal cancer patients with NRAS exon 4 mutations (PMID: 36307056; ESMO.org). | 36307056 detail... |
NRAS exon4 | colon cancer | resistant | Panitumumab | Guideline | Actionable | Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org). | detail... |
NRAS wild-type | colon cancer | predicted - sensitive | Panitumumab | Guideline | Actionable | Vectibix (panitumumab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic colon cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
NRAS wild-type | rectum cancer | predicted - sensitive | Panitumumab | Guideline | Actionable | Vecitbix (panitumumab), alone and in combination with chemotherapy, is included in guidelines for patients with advanced or metastatic rectal cancer that is BRAF wild-type, KRAS wild-type, and NRAS wild-type (NCCN.org). | detail... |
BRAF V600E | colorectal cancer | resistant | Panitumumab | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, the addition of Erbitux (cetuximab) or Vectibix (panitumumab) to standard of care treatment with chemotherapy did not result in improved progression-free survival (HR=0.88; 95% CI, 0.67-1.14; p=0.33), overall survival (HR=0.91; 95% CI, 0.62-1.34; p=0.63), or objective response rate (relative risk=1.31; 95% CI, 0.83-2.08; p=0.25) in patients with advanced colorectal cancer harboring BRAF V600E (PMID: 25673558). | 25673558 |
NRAS G115Efs*46 | colorectal cancer | predicted - resistant | Panitumumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). | 32796636 |
BRAF class 2 | colorectal cancer | decreased response | Panitumumab | Clinical Study | Actionable | In a clinical study, colorectal cancer patients harboring class 2 BRAF mutations demonstrated a decreased response to treatment with the combination of either Erbitux (cetuximab) or Vectibix (panitumumab) plus chemotherapy compared to those with class 3 BRAF mutations, with a response rate of 8% (1/12) vs 50% (14/28) (P=0.02), respectively, in first, second, third or later-line setting and a response rate of 17% (1/6) vs 78% (7/9) (P=0.04), respectively, in the first or second-line setting (PMID: 31515458). | 31515458 |
BRAF V600E | colorectal cancer | resistant | Panitumumab | Clinical Study | Actionable | In a retrospective analysis, metastatic colorectal cancer patients harboring BRAF V600E demonstrated shorter progression-free survival (p=0.0107) and overall survival (p<0.0001) compared to patients with wild-type BRAF following Vectibix (panitumumab) or Erbitux (cetuximab) therapy with or without chemotherapy, and in a preclinical study, colorectal cancer cell lines harboring BRAF V600E were resistant to Vectibix (panitumumab) in culture (PMID: 19001320). | 19001320 |
BRAF K601E | colorectal cancer | predicted - resistant | Panitumumab | Case Reports/Case Series | Actionable | In a clinical study, Vectibix (panitumumab) treatment as a third-line therapy resulted in progressive disease in a metastatic colorectal cancer patient harboring BRAF K601E (PMID: 31515458). | 31515458 |
MAP2K1 K57N | colorectal cancer | resistant | Panitumumab | Case Reports/Case Series | Actionable | In a retrospective analysis, two patients with metastatic RAS/BRAF wild-type colorectal cancer demonstrated progressive disease following treatment with Vectibix (panitumumab) and via analysis of archived pretreatment tumor biopsy samples and post-progression liquid biopsy both were found to harbor MAP2K1 K57N (PMID: 36419886). | 36419886 |
HRAS G12V | Advanced Solid Tumor | resistant | Panitumumab | Preclinical | Actionable | In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062). | 22797062 |
MAP2K1 K57N | colorectal cancer | resistant | Panitumumab | Preclinical | Actionable | In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315). | 26644315 |
MAP2K1 K57T | colorectal cancer | resistant | Panitumumab | Preclinical | Actionable | In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315). | 26644315 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01910610 | Phase III | Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) | Active, not recruiting | ISR | IRL | FRA | 0 |
NCT03087071 | Phase II | Panitumumab Panitumumab + Trametinib | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03992456 | Phase II | Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04787341 | Phase II | Regorafenib Panitumumab | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) | Active, not recruiting | ITA | 0 |
NCT00113763 | Phase III | Panitumumab | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | Completed | 0 | |
NCT00610948 | Phase I | Everolimus Panitumumab | Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment | Completed | USA | 0 |
NCT00658658 | Phase I | Panitumumab | Panitumumab Pediatric Study | Completed | USA | 0 |
NCT00842257 | Phase II | Panitumumab | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | Completed | USA | 0 |
NCT00979212 | Phase II | Panitumumab Carboplatin + Paclitaxel | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) | Completed | USA | 0 |
NCT01001377 | Phase III | Cetuximab Panitumumab | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | SWE | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | GBR | FRA | CZE | CAN | BGR | BEL | AUS | 12 |
NCT01202409 | Phase II | Panitumumab | CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | Completed | USA | 0 |
NCT01260415 | Phase II | Panitumumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin | A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases | Completed | CAN | 0 |
NCT01312857 | Phase II | Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer | Completed | USA | 0 |
NCT01814501 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | Completed | USA | 0 |
NCT01927341 | Phase Ib/II | Binimetinib Panitumumab | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | Completed | USA | NLD | ITA | FRA | ESP | CAN | BEL | 0 |
NCT02415881 | Phase I | Panitumumab | Phase I Panitumumab IRDye800 Optical Imaging Study | Completed | USA | 0 |
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab Pemigatinib | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT03510208 | Phase Ib/II | Panitumumab | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | Recruiting | USA | 0 |
NCT04587128 | Phase II | Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | Recruiting | USA | 0 |
NCT05845450 | Phase II | Durvalumab Trastuzumab deruxtecan Panitumumab + Sotorasib Vorbipiprant Balstilimab + Botensilimab Nivolumab + Vorbipiprant Panitumumab Botensilimab | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | Recruiting | ITA | 0 |
NCT06314997 | Phase II | Panitumumab | Dynamic Changes in Circulating Tumour Cells Protein Expression (Liquid-DRER2) | Recruiting | ITA | 0 |
NCT01128387 | Phase Ib/II | Fluorouracil Panitumumab Cisplatin | Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer | Terminated | USA | 0 |
NCT02448810 | Phase II | Fluorouracil + Leucovorin Imalumab Panitumumab | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02508077 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | Terminated | USA | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: